Publications
Immodulon and Champalimaud Foundation announce collaboration to investigate IMM-101 in difficult to treat cancers
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
Immodulon announces that IMM-101 will be evaluated in world-first, prophylactic immuneboosting strategy for COVID-19 in cancer patients
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...
Immodulon announces presentations at CICON, BSI and Pancreatic Cancer Symposium
Poster presentation at CICON and oral and poster presentation at BSI demonstrated the immunomodulatory effects of IMM-101 in pre-clinical models Oral and poster presentation at Pancreatic Cancer Symposium reported results from the IMAGE 1 open label Phase II study in...